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Abstract The 825T allele of a common C825T polymorphism in
the gene encoding the L3 subunit of heterotrimeric G proteins is
associated with enhanced activation of pertussis toxin (PTX)-
sensitive G proteins. We investigated responses of human
platelets upon stimulation with epinephrine, which activates
PTX-sensitive G proteins, and with agonists which activate
additionally, or exclusively PTX-insensitive pathways. Slopes
and maximum of the secondary aggregation were significantly
enhanced in platelets from 825T allele carriers after epinephrine,
and after combined epinephrine/ADP. This effect was more
pronounced after inhibition of the cyclooxygenase-2 pathway by
acetylsalicylic acid. This phenomenon appeared independent of
platelet secretion, or inhibition of the adenylyl cyclase. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The G protein K subunits which are activated in human
platelets by common agonists have been described: vasopres-
sin (VP) induces platelet aggregation via the V1 receptor in-
volving the pertussis toxin (PTX)-insensitive GKq [1]. The
thromboxane A2 (TXA2) receptor agonist U46619 activates
GK12, GK13, GKq but not the PTX-sensitive GKi [2,3].
Thrombin receptor-activating peptide (TRAP) activates
GK12, GK13, GKq, and GKi [2,4]. ADP activates GKq and
GKi [5]. Using a knockout mouse model, O¡ermanns et al.
documented that GKq is essential for aggregation in response
to TXA2, thrombin, and ADP [6], whereas GK12/13 proteins
mediate the platelet shape change reaction [7]. In contrast,
epinephrine-induced platelet aggregation is considered to be
exclusively mediated by GKi2 after activation of the K2A adre-
noceptor [8].
We have described a common C825T polymorphism in the
gene GNB3, encoding the ubiquitously expressed L3 subunit
of heterotrimeric G proteins [9]. The 825T allele is associated
with alternative splicing of the gene and the generation of a
truncated, but functionally active L subunit referred to as
GL3s. GL3s was demonstrated to be expressed in platelets
of 825T allele carriers by means of Western blot analysis [9],
and the 825T allele is predictive of enhanced signal transduc-
tion via PTX-sensitive G proteins [9^11].
Given the activation of PTX-sensitive G proteins by epi-
nephrine together with the observation that the K2A adreno-
ceptor activates G protein heterotrimers containing GL3 [12],
we hypothesized that epinephrine-mediated platelet aggrega-
tion should be enhanced in GNB3 825T allele carriers. In
contrast, platelet activation evoked by thrombin, ADP, or
U46619, TRAP and VP may not be in£uenced by the allele
status at the 825 positions of GNB3.
2. Materials and methods
Only healthy, non-smoking, male individuals between 18 and 40
years of age with no medication known to interfere with platelet
function for at least 15 days were enrolled. Fura 2-acetoxymethylester
and the thromboxane agonist U46619 were purchased from Calbio-
chem (La Jolla, CA, USA). Thrombin receptor agonist (TRAP) and
bovine [Arg8]-VP were obtained from Calbiochem^Novabiochem (San
Diego, CA, USA). Epinephrine (Suprarenin1) was purchased from
Hoechst AG (Frankfurt, Germany). Acetylsalicylic acid, forskolin,
ADP, and thrombin were obtained from Sigma (Deisenhofen, Ger-
many).
Platelet-rich plasma and platelet-poor plasma (PPP) were prepared
as previously described [13]. All measurements were conducted within
3 h after preparation of platelets. Aggregation was monitored over 10
min using a single channel aggregometer (Chrono-Log Model 500-
CA, Haverton, PA, USA) with continuous stirring at 900 rpm, pre-
warmed at 37‡C, and calibrated before each single measurement. In-
tracellular Ca2 concentration [Ca2]i was determined in Fura 2-
loaded platelets as described [13], using a spectro£uorometer (LS-
5B, Perkin Elmer Corporation, Germany). Platelet overall secretion
was estimated by analysis of the expression of P-selectin (CD62) as a
marker of K degranulation, and GP53 (CD63) as a marker of dense
granule secretion by use of an EPICS XL £ow cytometer (Beckman
Coulter, USA) mainly as described [14]. Intracellular cAMP concen-
trations were measured by a radioimmunoassay (Amersham Pharma-
cia Biotech, Freiburg, Germany) following the manufacturer’s recom-
mendations. Genotype analysis was performed as described [9]. The
mean of triplicate measurements was calculated and groups were com-
pared using Student’s t-test for continuous variables. Di¡erences were
regarded signi¢cant at P6 0.05.
3. Results and discussion
Addition of epinephrine evoked the typical biphasic aggre-
gation pattern seen in citrated plasma, the ¢rst phase repre-
senting primary (reversible) aggregation and the second phase
representing secondary aggregation, which is initiated by the
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release of prostaglandin endoperoxide and platelet granule
contents [15]. Primary aggregation was virtually identical in
C825 and 825T allele carriers (data not shown). The slope of
the secondary aggregation was approximately 2-fold increased
in 825T allele carriers following stimulation with 1, 2, and 10
WM epinephrine, and the total extent of secondary aggrega-
tion was signi¢cantly higher at 1 and 2 WM epinephrine (Fig.
1). Epinephrine is known as a weak platelet agonist, which is
capable to enhance the response to other agonists such as
ADP, even in concentrations that usually evoke no, or only
slight aggregatory responses [16]. After the combination of 0.5
WM ADP with low doses of epinephrine, the slope of the
aggregatory response was signi¢cantly enhanced in carriers
of an 825T allele at GNB3, however, the maximum response
remained unchanged (Fig. 2). Most interestingly, the inhibi-
tion of the cyclooxygenase-2 pathway by acetylsalicylic acid
leads to an even more pronounced and clearly signi¢cant dif-
ference between the genotypes (Fig. 2).
In contrast, after addition of ADP, U46619 and TRAP, the
maximal slopes of the increase of light transmission as well as
the maximal amplitudes of the reactions were not signi¢cantly
di¡erent between genotypes at GNB3 (Fig. 3).
Platelets from 825T allele carriers displayed also signi¢-
cantly higher basal values of [Ca2]i compared to platelets
from homozygous C825 allele carriers (133 þ 17.4 nM versus
92 þ 9.9 nM; P6 0.05; Fig. 4). This ¢nding is interesting,
since an increased basal [Ca2]i has repeatedly been found
in cells from hypertensive individuals [17] and, therefore,
keeps in line with the reported association of the 825T allele
with hypertension [8,18,19]. This di¡erence in [Ca2]i disap-
peared after agonist stimulation, and might, therefore, re£ect
a certain rate of pre-stimulation by e.g. enhanced sympathetic
tone in these individuals.
These ¢ndings support our hypothesis that the 825T allele is
a marker of enhanced signal transduction via pathways in-
Fig. 1. Slope and maximum of the secondary aggregation after epi-
nephrine. Light transmission is given as % PPP. F GNB3 825 TT
and TC (n = 16); E GNB3 825 CC (n = 18); *P6 0.05.
Fig. 2. Slope and maximum of the secondary aggregation after the
combination of epinephrine and ADP before and after incubation
with 1 mM acetylsalicylic acid. Light transmission is given as % of
PPP. F GNB3 825 TT and TC (n = 16); E GNB3 825 CC (n = 18);
P6 0.05.
Fig. 3. Slope of aggregation and maximum of aggregation after
stimulation with ADP, U46619, and TRAP. Light transmission is
given as % of PPP. F GNB3 825 TT and TC (n = 16); E GNB3 825
CC (n = 18).
Fig. 4. Changes of [Ca2]i after thrombin and VP. F GNB3 825 TT
and TC (n = 16); E GNB3 825 CC (n = 18); *P6 0.05.
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cluding mainly PTX-sensitive G proteins whereas no interfer-
ence with signaling via PTX-insensitive G proteins is ob-
served. Exclusively the secondary, irreversible aggregation
which comes along with secretion at the plasma membrane
[15] is enhanced in platelets of 825T allele carriers in response
to epinephrine. Thus, we decided to measure platelet overall
secretion by £ow cytometric analysis. However, neither the
expression of P-selectin (CD62) as a marker of K degranula-
tion, nor that of GP53 (CD63) as a marker of dense granule
degranulation displayed di¡erences between the genotypes
(Fig. 5). As aggregation in response to platelet secretion prod-
ucts, such as ADP and TXA2, was similar between genotypes
at GNB3 (Fig. 2), it appears unlikely that di¡erences in plate-
let secretion can explain the increased responses of 825T allele
carriers to epinephrine.
To further investigate the potential mechanisms resulting in
the enhanced platelet response to epinephrine in carriers of
the 825T allele at GNB3, we investigated cAMP levels at base-
line and the inhibition of forskolin-stimulated adenylyl cyclase
activity by 1 and 10 WM epinephrine. These were, however,
not signi¢cantly di¡erent between genotypes (Fig. 6). Like-
wise, Pietruck et al. [20] also found no signi¢cant di¡erences
regarding inhibition of forskolin-stimulated cAMP levels in
skin ¢broblasts with an overall increased reactivity of PTX-
sensitive G proteins which was later shown to depend on the
presence or absence of an 825T allele at GNB3 [9].
Future studies will have to unravel the step(s) which ulti-
mately result in enhanced epinephrine-mediated aggregation
in platelets from 825T allele carriers, which appears independ-
ent of inhibition of adenylyl cyclase activity or platelet secre-
tion. Since epinephrine is commonly regarded a modulator of
platelet activation by weak agonists [16], a function which
appears to be also enhanced in our population, our ¢ndings
lead to the hypothesis that under physiological conditions, e.g.
during sympathetic activation, the enhanced reactivity of
platelet GKi proteins in 825T allele carriers may increase
platelet aggregation in vivo. Whether or not the observed
di¡erence concerning the response to acetylsalicylic acid may
also a¡ect the therapeutic use of the substance as anti-aggre-
gatory therapy remains to be determined.
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Fig. 5. Expression of P-selectin (CD62) and GP53 (CD63) after epi-
nephrine in the presence of 0.5 WM ADP. F GNB3 825 TT and TC
(n = 14); E GNB3 825 CC (n = 16).
Fig. 6. Intracellular cAMP concentrations after 1 h incubation with
1 WM forskolin and after inhibition of adenylylcyclase by simultane-
ous incubation with epinephrine. F GNB3 825 TT and TC (n = 9);
E GNB3 825 CC (n = 11).
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